Nasdaq Accepts Evofem Plan to Regain Listing Compliance

Continued Listing Subject to Receipt of Shareholder Approval for the Reverse Stock Split of Evofem Common Stock before May 4, 2022, with Compliance by May 20, 2022 SAN DIEGO, April 7, 2022 /PRNewswire/ — Evofem Biosciences, Inc. (Nasdaq: EVFM) (“Evofem” and the “Company”), a…

Click here to view original post